WebSep 23, 2024 · for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% … WebJun 17, 2024 · Results of the VERTIS-CV trial indicate ertugliflozin could reduce heart failure hospitalizations but did not demonstrate the ability to reduce MACE compared to placebo. News. Media. Medical World News. Podcasts. Shows. State Of Sciences - Presentations. Videos. Webinars. Multimedia Series.
Added Ertugliflozin Heart Failure Data Show It’s Best in …
WebMay 17, 2024 · In heart failure with reduced ejection fraction—a better known, more treatable form of the disease—weakness of the heart muscle means that only 40% or … WebThe VERTIS-CV trial reaffirms the reduction in heart failure hospitalizations as a likely class effect of SGLT-2 inhibitors. While the trial supports the use of ertugliflozin beyond … robert half wage
Evaluation of Ertugliflozin Efficacy and Safety …
WebOct 7, 2024 · A total of 8246 patients were randomly assigned to ertugliflozin (n=5499) or placebo (n=2747); n=1958 (23.7%) had a history of heart failure (HF) and n=5006 (60.7%) had pretrial ejection fraction (EF) available, including n=959 with EF ≤45%. Ertugliflozin did not significantly reduce first HHF/CV death (hazard ratio [HR], 0.88 [95% CI, 0.75–1.03]). WebApr 10, 2024 · Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure ... Dagogo-Jack S, et al.: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2024, 383:1425-35. 10.1056/NEJMoa2004967 16. Perkovic V, Jardine MJ, Neal B, et al.: Canagliflozin and … Web18 hours ago · Abstract. Patients with chronic kidney disease (CKD) are at high risk to develop cardiovascular disease with its manifestations coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. In addition, the presence of CKD has a major impact on the prognosis of patients with cardiovascular disease, leading to an … robert half w-2